Another study demonstrated superior cancer-specific survival (HR 0.18; 95% CI 0.06 to 0.61; p < 0.001) when aspirin was used after CRC diagnosis in tumors with PIK3CA mutation. Here, PIK3CA is linked to colorectal carcinoma.